Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
601 questions in 75 reviews · Schizophrenia
current versionsNo studies 601 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
HEALTHY LIVING STUDY CIRCLE vs AESTHETIC STUDY CIRCLE Physical health behaviour ‐ not measured · patients with people with serious mental illness General physical health advice for people with serious mental illness (2014) · Cochrane | no estimate extracted | NR | No studies |
HEALTHY LIVING STUDY CIRCLE vs AESTHETIC STUDY CIRCLE Quality of life ‐ not measured · patients with people with serious mental illness General physical health advice for people with serious mental illness (2014) · Cochrane | no estimate extracted | NR | No studies |
HEALTHY LIVING STUDY CIRCLE vs AESTHETIC STUDY CIRCLE Adverse Effects ‐ not reported · patients with people with serious mental illness General physical health advice for people with serious mental illness (2014) · Cochrane | no estimate extracted | NR | No studies |
HEALTHY LIVING STUDY CIRCLE vs AESTHETIC STUDY CIRCLE Economic ‐ not reported · patients with people with serious mental illness General physical health advice for people with serious mental illness (2014) · Cochrane | no estimate extracted | NR | No studies |
PHYSICAL HEALTH ADVICE vs STANDARD CARE Economic ‐ not reported · patients with people with serious mental illness General physical health advice for people with serious mental illness (2014) · Cochrane | no estimate extracted | NR | No studies |
HEALTH EDUCATION vs HEALTH EMPOWERMENT EDUCATION Physical health awareness ‐ not reported · people with serious mental illness General physical health advice for people with serious mental illness (2014) · Cochrane | no estimate extracted | NR | No studies |
HEALTH EDUCATION vs HEALTH EMPOWERMENT EDUCATION Physical health behaviour ‐ not measured · people with serious mental illness General physical health advice for people with serious mental illness (2014) · Cochrane | no estimate extracted | NR | No studies |
Horticultural therapy plus standard care vs standard care alone Clinical global response · patients with schizophrenia Horticultural therapy for schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
Horticultural therapy plus standard care vs standard care alone General functioning · patients with schizophrenia Horticultural therapy for schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
Horticultural therapy plus standard care vs standard care alone Physical fitness · patients with schizophrenia Horticultural therapy for schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
Horticultural therapy plus standard care vs standard care alone Adverse effect · patients with schizophrenia Horticultural therapy for schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
BRIEF FAMILY INTERVENTION vs STANDARD CARE Service utilisation ‐ days in hospital ‐ medium to long term ‐ not reported · patients with schizophrenia Family intervention (brief) for schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
BRIEF FAMILY INTERVENTION vs STANDARD CARE Global state ‐ compliance with medication ‐ medium to long term ‐ not reported · patients with schizophrenia Family intervention (brief) for schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
BRIEF FAMILY INTERVENTION vs STANDARD CARE Quality of life/satisfaction with care ‐ for recipients or carers ‐ medium to long term ‐ not reported · patients with schizophrenia Family intervention (brief) for schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
BRIEF FAMILY INTERVENTION vs STANDARD CARE Economic outcomes ‐ costs of care ‐ long term ‐ not reported · patients with schizophrenia Family intervention (brief) for schizophrenia (2014) · Cochrane | no estimate extracted | NR | No studies |
INFORMATION AND COMMUNICATION TECHNOLOGY (ICT) FOR PROMPTING/SUPPORT + STANDARD CARE vs STANDARD CARE Service utilisation ‐ not reported · patients with treatment compliance for people with serious mental illness Information and communication technology based prompting for treatment compliance for people with serious… (2014) · Cochrane | no estimate extracted | NR | No studies |
User‐held information vs standard information Death: causes other than suicide ‐ not reported · patients with routine care of people with severe mental illness User‐held personalised information for routine care of people with severe mental illness (2013) · Cochrane | no estimate extracted | NR | No studies |
User‐held information vs standard information Violence ‐ not reported · patients with routine care of people with severe mental illness User‐held personalised information for routine care of people with severe mental illness (2013) · Cochrane | no estimate extracted | NR | No studies |
PIMOZIDE vs ANY ANTIPSYCHOTIC Quality of life: no significant change in quality of life/satisfaction medium term (3‐12 months) not reported · patients with schizophrenia or related psychoses Pimozide for schizophrenia or related psychoses (2013) · Cochrane | no estimate extracted | NR | No studies |
PIMOZIDE + ANY ANTIPSYCHOTIC vs ANY ANTIPSYCHOTIC Mental state: no improvementmedium term (3‐12 months)not reported · patients with schizophrenia or related psychoses Pimozide for schizophrenia or related psychoses (2013) · Cochrane | no estimate extracted | NR | No studies |
PIMOZIDE + ANY ANTIPSYCHOTIC vs ANY ANTIPSYCHOTIC Mental state: presence of first‐rank symptoms medium term (3‐12 months)not reported · patients with schizophrenia or related psychoses Pimozide for schizophrenia or related psychoses (2013) · Cochrane | no estimate extracted | NR | No studies |
PIMOZIDE + ANY ANTIPSYCHOTIC vs ANY ANTIPSYCHOTIC Adverse effects: extrapyramidal adverse effects Parkinsonismshort term (< 3 months) not reported · patients with schizophrenia or related psychoses Pimozide for schizophrenia or related psychoses (2013) · Cochrane | no estimate extracted | NR | No studies |
PIMOZIDE + ANY ANTIPSYCHOTIC vs ANY ANTIPSYCHOTIC Adverse effects: extrapyramidal adverse effects Parkinsonismmedium term (3‐12 months) not reported · patients with schizophrenia or related psychoses Pimozide for schizophrenia or related psychoses (2013) · Cochrane | no estimate extracted | NR | No studies |
PIMOZIDE vs PLACEBO Mental state: no improvement medium term (3‐12 months) not reported · patients with schizophrenia or related psychoses Pimozide for schizophrenia or related psychoses (2013) · Cochrane | no estimate extracted | NR | No studies |
PIMOZIDE + ANY ANTIPSYCHOTIC vs ANTIPSYCHOTIC + PLACEBO Mental state: no improvement medium term (3‐12 months) not reported · patients with schizophrenia or related psychoses Pimozide for schizophrenia or related psychoses (2013) · Cochrane | no estimate extracted | NR | No studies |
PIMOZIDE + ANY ANTIPSYCHOTIC vs ANTIPSYCHOTIC + PLACEBO Mental state: presence of first‐rank symptoms medium term (3‐12 months) not reported · patients with schizophrenia or related psychoses Pimozide for schizophrenia or related psychoses (2013) · Cochrane | no estimate extracted | NR | No studies |
PIMOZIDE + ANY ANTIPSYCHOTIC vs ANTIPSYCHOTIC + PLACEBO Adverse effects: extrapyramidal adverse effects Parkinsonism short term (< 3 months) not reported · patients with schizophrenia or related psychoses Pimozide for schizophrenia or related psychoses (2013) · Cochrane | no estimate extracted | NR | No studies |
PIMOZIDE + ANY ANTIPSYCHOTIC vs ANTIPSYCHOTIC + ANTIPSYCHOTIC Global state: relapse medium term (3‐12 months) not reported · patients with schizophrenia or related psychoses Pimozide for schizophrenia or related psychoses (2013) · Cochrane | no estimate extracted | NR | No studies |
PIMOZIDE + ANY ANTIPSYCHOTIC vs ANTIPSYCHOTIC + ANTIPSYCHOTIC Mental state: no improvement medium term (3‐12 months) not reported · patients with schizophrenia or related psychoses Pimozide for schizophrenia or related psychoses (2013) · Cochrane | no estimate extracted | NR | No studies |
PIMOZIDE + ANY ANTIPSYCHOTIC vs ANTIPSYCHOTIC + ANTIPSYCHOTIC Mental state: presence of first‐rank symptoms medium term (3‐12 months) not reported · patients with schizophrenia or related psychoses Pimozide for schizophrenia or related psychoses (2013) · Cochrane | no estimate extracted | NR | No studies |
PIMOZIDE vs PLACEBO Mental state: specific symptoms first‐rank symptoms medium term (3‐12 months) not reported · patients with schizophrenia or related psychoses Pimozide for schizophrenia or related psychoses (2013) · Cochrane | no estimate extracted | NR | No studies |
PIMOZIDE + ANY ANTIPSYCHOTIC vs ANTIPSYCHOTIC + ANTIPSYCHOTIC Quality of life: average change score medium term (3‐12 months) not reported · patients with schizophrenia or related psychoses Pimozide for schizophrenia or related psychoses (2013) · Cochrane | no estimate extracted | NR | No studies |
PIMOZIDE vs PLACEBO Quality of life: no significant change in quality of life/satisfaction medium term (3‐12 months) not reported · patients with schizophrenia or related psychoses Pimozide for schizophrenia or related psychoses (2013) · Cochrane | no estimate extracted | NR | No studies |
DANCE THERAPY vs STANDARD CARE Service utilisation‐days in hospital · patients with schizophrenia Dance therapy for schizophrenia (2013) · Cochrane | no estimate extracted | NR | No studies |
NIDOTHERAPY‐ENHANCED STANDARD CARE vs STANDARD CARE Functioning ‐ general ‐ no important change ‐ medium term (6‐12 months) ‐ not measured · patients with people with schizophrenia Nidotherapy for people with schizophrenia (2013) · Cochrane | no estimate extracted | NR | No studies |
NIDOTHERAPY‐ENHANCED STANDARD CARE vs STANDARD CARE Quality of life ‐ no important change ‐ medium term (6‐12 months) ‐ not measured · patients with people with schizophrenia Nidotherapy for people with schizophrenia (2013) · Cochrane | no estimate extracted | NR | No studies |
ADJUNCTIVE TREATMENT ‐ NON‐SPECIFIC: SELEGILINE vs PLACEBO Quality of life Not reported · patients with sexual dysfunction due to antipsychotic drug therapy Management of sexual dysfunction due to antipsychotic drug therapy (2012) · Cochrane | no estimate extracted | NR | No studies |
ADJUNCTIVE TREATMENT ‐ NON‐SPECIFIC: SELEGILINE vs PLACEBO Adverse effects: Death Not reported · patients with sexual dysfunction due to antipsychotic drug therapy Management of sexual dysfunction due to antipsychotic drug therapy (2012) · Cochrane | no estimate extracted | NR | No studies |
SWITCHING ANTIPSYCHOTIC: TO QUETIAPINE vs MAINTENANCE RISPERIDONE Quality of life Not reported · patients with sexual dysfunction due to antipsychotic drug therapy Management of sexual dysfunction due to antipsychotic drug therapy (2012) · Cochrane | no estimate extracted | NR | No studies |
SWITCHING ANTIPSYCHOTIC: TO QUETIAPINE vs MAINTENANCE RISPERIDONE Adverse effects: Death Not reported · patients with sexual dysfunction due to antipsychotic drug therapy Management of sexual dysfunction due to antipsychotic drug therapy (2012) · Cochrane | no estimate extracted | NR | No studies |
SWITCHING ANTIPSYCHOTIC: TO QUETIAPINE vs MAINTENANCE RISPERIDONE Adverse effects: Extrapyramidal symptoms Not reported · patients with sexual dysfunction due to antipsychotic drug therapy Management of sexual dysfunction due to antipsychotic drug therapy (2012) · Cochrane | no estimate extracted | NR | No studies |
SWITCHING ANTIPSYCHOTIC: TO OLANZAPINE vs MAINTENANCE RISPERIDONE/FGA Quality of life Not reported · patients with sexual dysfunction due to antipsychotic drug therapy Management of sexual dysfunction due to antipsychotic drug therapy (2012) · Cochrane | no estimate extracted | NR | No studies |
SWITCHING ANTIPSYCHOTIC: TO OLANZAPINE vs MAINTENANCE RISPERIDONE/FGA Adverse effects: Death Not reported · patients with sexual dysfunction due to antipsychotic drug therapy Management of sexual dysfunction due to antipsychotic drug therapy (2012) · Cochrane | no estimate extracted | NR | No studies |
ADJUNCTIVE TREATMENT ‐ SPECIFIC: SILDENAFIL vs PLACEBO Quality of life Not reported · patients with sexual dysfunction due to antipsychotic drug therapy Management of sexual dysfunction due to antipsychotic drug therapy (2012) · Cochrane | no estimate extracted | NR | No studies |
ADJUNCTIVE TREATMENT ‐ SPECIFIC: SILDENAFIL vs PLACEBO Adverse effects: Death Not reported · patients with sexual dysfunction due to antipsychotic drug therapy Management of sexual dysfunction due to antipsychotic drug therapy (2012) · Cochrane | no estimate extracted | NR | No studies |
ADJUNCTIVE TREATMENT ‐ SPECIFIC: SILDENAFIL vs PLACEBO Adverse effects: Psychotic symptoms Not reported · patients with sexual dysfunction due to antipsychotic drug therapy Management of sexual dysfunction due to antipsychotic drug therapy (2012) · Cochrane | no estimate extracted | NR | No studies |
ADJUNCTIVE TREATMENT ‐ SPECIFIC: SILDENAFIL vs PLACEBO Adverse effects: Extrapyramidal symptoms Not reported · patients with sexual dysfunction due to antipsychotic drug therapy Management of sexual dysfunction due to antipsychotic drug therapy (2012) · Cochrane | no estimate extracted | NR | No studies |
BENZODIAZEPINES AS SOLE TREATMENT vs PLACEBO Number of participants tranquillised at endpoint of the study (Desired sedation/tranquillisation) · people with schizophrenia Benzodiazepines for schizophrenia (2012) · Cochrane | no estimate extracted | NR | No studies |
Paliperidone palmitate vs risperidone long‐acting injection Cost ‐ not measured · patients with schizophrenia Paliperidone palmitate for schizophrenia (2012) · Cochrane | no estimate extracted | NR | No studies |
Paliperidone palmitate vs risperidone long‐acting injection Health related quality of life ‐ not measured · patients with schizophrenia Paliperidone palmitate for schizophrenia (2012) · Cochrane | no estimate extracted | NR | No studies |